Literature DB >> 17389619

Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome?

Julia M Hofstra, Jeroen K J Deegens, Jack F M Wetzels.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17389619     DOI： 10.1093/ndt/gfm128

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  18 in total

1.  American Society of Nephrology quiz and questionnaire 2013: glomerulonephritis.

Authors:  Fernando C Fervenza; Mark A Perazella; Michael J Choi
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

Review 2.  Rituximab and minimal change nephrotic syndrome: a therapeutic option.

Authors:  Takashi Takei; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2011-05-26       Impact factor: 2.801

3.  Rituximab efficiency in children with steroid-dependent nephrotic syndrome.

Authors:  Anne-Laure Sellier-Leclerc; Marie-Alice Macher; Chantal Loirat; Valérie Guérin; Hervé Watier; Michel Peuchmaur; Véronique Baudouin; Georges Deschênes
Journal:  Pediatr Nephrol       Date:  2010-03-18       Impact factor: 3.714

4.  Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome.

Authors:  Yoei Miyabe; Takashi Takei; Yuko Iwabuchi; Takahito Moriyama; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2015-07-03       Impact factor: 2.801

Review 5.  Nephrotic syndrome and rituximab: facts and perspectives.

Authors:  Dieter Haffner; Dagmar-Christiane Fischer
Journal:  Pediatr Nephrol       Date:  2009-06-04       Impact factor: 3.714

Review 6.  Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible?

Authors:  Jörg Dötsch; Dirk E Müller-Wiefel; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2007-09-26       Impact factor: 3.714

7.  Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome?

Authors:  Laëtitia Delbe-Bertin; Bilal Aoun; Elena Tudorache; Hélène Lapillone; Tim Ulinski
Journal:  Pediatr Nephrol       Date:  2012-12-05       Impact factor: 3.714

8.  Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.

Authors:  Stéphanie Tellier; Karine Brochard; Arnaud Garnier; Flavio Bandin; Brigitte Llanas; Vincent Guigonis; Mathilde Cailliez; Christine Pietrement; Olivier Dunand; Sylvie Nathanson; Aurélia Bertholet-Thomas; Lydia Ichay; Stéphane Decramer
Journal:  Pediatr Nephrol       Date:  2013-01-23       Impact factor: 3.714

9.  Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children.

Authors:  Koichi Kamei; Shuichi Ito; Kandai Nozu; Shuichiro Fujinaga; Makiko Nakayama; Mayumi Sako; Mari Saito; Maki Yoneko; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2009-05-07       Impact factor: 3.714

10.  Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab.

Authors:  Megha Suri; Kim Tran; Ajay P Sharma; Guido Filler; Joanne Grimmer
Journal:  Int Urol Nephrol       Date:  2008-05-20       Impact factor: 2.370
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.